Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Genentech, Inc. unveiled a partnership on 2 February with X-Chem, Inc. to discover and develop novel small molecule treatments in oncology; the deal also confers an exclusive license to a set of preclinical novel compounds discovered by X-Chem
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?